

Early treatment with metformin improves neurological outcomes in Lafora disease

Daniel F. Burgos, MSc^{*, †, ‡}; María Machío-Castello, MD^{*, †}; Nerea Iglesias-Cabeza, MSc^{*, †}; Beatriz G. Giráldez, MD^{*, †}; Juan González-Fernández, PhD^{*, †, §}; Gema Sánchez-Martín, Tech^{*, †}; Marina P. Sánchez, PhD^{*, †}; José M. Serratosa, MD, PhD^{*, †, ¶}

* Laboratory of Neurology, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Autonoma de Madrid University (IIS-FJD, UAM), 28040 Madrid, Spain

† Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain

‡ PhD Program in Neuroscience, Autonoma de Madrid University-Cajal Institute, 28029 Madrid, Spain

§ Present address: Department of Parasitology, School of Pharmacy, Complutense de Madrid University, 28040 Madrid, Spain.

¶ **Corresponding author:** Jose M. Serratosa, MD, Ph.D

Corresponding author's address: Avda Reyes Católicos, 2 28040 Madrid, Spain

Corresponding author's phone and fax: Phone: 34-91-5504800 Ext. 3451; Fax: 34-91-5497700

Corresponding author's e-mail address: joseserratosa@me.com

Running title: Early metformin as a therapy for Lafora disease




Fig. s1 Variations in each category of the LESS from the initial examination to 6, 12, 18 and 24 months of follow-up in patients with Lafora disease. We calculated the variation in the LESS score from the initial examination to 6, 12, 18 and 24 months of follow-up. Thus, to calculate all these variations, we always used the LESS score reported in the baseline follow-up as the reference, in order to identify the most well-preserved alterations due to metformin administration. Data are shown as a mean of the variations in the LESS \pm SEM. A Student's t-test was performed when we analyzed data at the initial examination, and at 6, 12 and 18 months of follow-up. We used the Mann-Whitney non-parametric test when we studied data at 24 months. * $p < 0.05$; ** $p < 0.01$